We investigated the effects of two novel copper-based inorganic formulations for their activity against 60 isolates of Helicobacter pylori (Hp). The two copper-based formulations were tested against three NCTC Helicobacter pylori isolates and 57 clinical strains isolated from the UK and Italy in time-kill assays. Both copper-based formulations were bio-cidal against all Helicobacter pylori strains tested reducing the viable count by 4–5 log within 2 h. These two copper-based anti-microbial agents deserve further study in relation to the treatment of H. pylori-related gastric disease.
References
[1]
Warren, J.R.; Marshall, B.J. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983, I, 1273–1275.
[2]
Sung, J.J.; Kuipers, E.J.; El-Serag, H.B. The global incidence and prevalence of PUD. Aliment. Pharmacol. Ther. 2009, 29, 938–946, doi:10.1111/j.1365-2036.2009.03960.x.
[3]
Atherton, J.C. The clinical relevance of strain types of Helicobacter pylori. Gut 1997, 40, 701–703, doi:10.1136/gut.40.6.701.
[4]
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Schistosomes, Liver Flukes and ; World Health Organization, International Agency for Research on Cancer: Lyon, France, 1994; Volume 61, pp. 1–241.
[5]
Santacroce, L.; Cagiano, R.; del Prete, D.; Bottalico, L.; Sabatini, R.; Carlaio, R.G.; Prejbeanu, R.; vermesan, H.; Dragulescu, S.I.; Vermesan, D.; et al. Helicobacter pylori infection and gastric MALToma: An up to date and therapeutic highlight. Clin. Ter. 2008, 159, 457–462.
Megraud, F. H pylori antibiotic resistance: Prevalence, importance and advances in testing. Gut 2004, 53, 1374–1384, doi:10.1136/gut.2003.022111.
[8]
Koletzko, S.; Richy, F.; Bontems, P.; Crone, J.; Lalach, N.; Monteiro, M.L.; Gottrand, F.; Celinska-Cedro, D.; Roma-Giannikou, E.; Oderda, G.; et al. Prospective multicentre study on antibiotic resistance of Helicobacter pylori strains obtained from children living in Europe. Gut 2006, 55, 1711–1716, doi:10.1136/gut.2006.091272.
[9]
Ramond, J.; Lamarque, D.; Kalach, N.; Chaussade, S.; Burucoa, C. High levels of antimicrobial resistance in French Helicobacter pylori isolates. Helicobacter 2010, 15, 21–27.
[10]
Agudo, S.; Alarcon, T.; Cibrelus, L.; Urruzuno, P.; Martinez, M.J.; Lopez-Brea, M. High percentage of clarithromycin and metronidazole resistance in Helicobacter pylori clinical isolates obtained from Spanish children. Rev. Esp. Quimioter. 2009, 22, 88–92.
[11]
Sasaki, M.; Ogasawara, N.; Utsumi, K.; Kawamura, N.; Kamiya, T.; Kataoka, H.; Tanida, S.; Mizoshita, T.; Kasugai, K.; Joh, T. Changes in 12 year first line eradication rate of Helicobacter pylori based on triple therapy with proton pump inhibitor, amoxicillin and clarithromycin. J. Clin. Biochem. Nutr. 2010, 47, 53–58, doi:10.3164/jcbn.10-10.
[12]
Gisbert, J.P.; Calvet, X.; O’Connor, A.; Megraud, F.; O’Morain, C. A Sequential therapy for Helicobacter pylori eradication: A critical review. J. Clin. Gastroenterol. 2010, 44, 313–325.
[13]
Jafri, N.S.; Hornung, C.A.; Howden, C.W. Meta analysis: Sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients na？ve to treatment. Ann. Int. Med. 2008, 148, 23–31.
[14]
Graham, D.Y.; Lu, H.; Yamaoka, Y. A report card to grade Helicobacter therapy. Helicobacter 2007, 12, 275–278, doi:10.1111/j.1523-5378.2007.00518.x.
[15]
Graham, D.Y.; Lu, H.; Yamaoka, Y. Therapy for Helicobacter pylori infection can be improved: Sequential therapy and beyond. Drugs 2008, 68, 725–736, doi:10.2165/00003495-200868060-00001.
[16]
Graham, D.Y. Efficient identification and evaluation of effective Helicobacter pylori therapies. Clin. Gastroenterol. Hepatol. 2009, 7, 145–148, doi:10.1016/j.cgh.2008.10.024.
[17]
Rotramel, A.; Poritz, L.S.; Messaris, E.; Berg, A.; Stewart, D.B. PPI therapy and albumen are better predictors of recurrent Clostridium difficile colitis than choice of antibiotics. J. Gastrointest. Surg. 2012, 16, 2267–2273.
[18]
Younson, J.; O’Mahony, R.; Liu, H.; Basset, C.; Grant, S.; Campion, C.; Jennings, L.; Vaira, D.; Kelly, C.G.; Roitt, I.M.; et al. Human domain antibody and Lewisb-glycoconjugate that inhibit binding of Helicobacter pylori to Lewisb receptor and adhesion to human gastric epithelium. J. Infect. Dis. 2009, 200, 1574–1582, doi:10.1086/644596.
[19]
Bedwell, J.; Holton, J.; Vaira, D.; MacRobert, A.J.; Bown, S.G. In vitro killing of Helicobacter pylori with photodynamic therapy. Lancet 1990, 335, 1287, doi:10.1016/0140-6736(90)91361-D.
[20]
O’Mahony, R.; Al-Khtheeri, H.; Weerasekera, D.; Fernando, N.; Vaira, D.; Holton, J.; Basset, C. Bactericidal and Anti-adhesive properties of culinary and medicinal plants against Helicobacter pylori. World J. Gastroenterol. 2005, 47, 7499–7507.
[21]
Boschian, A.; Jensen, C.S.; Rasmussen, L. Antibiotic effect of anti-malarials on H. pylori infection in vivo. Helicobacter 2010, 15, 335. Abstract.
[22]
Menghini, L.; Leporini, L.; Tirillini, B.; Epifano, F.; Genovese, S. Chemical composition and inhibitory activity against Helicobacter pylori of the essential oil of Apium nodiflorum (Apiaceae). J. Med. Food 2010, 13, 228–230, doi:10.1089/jmf.2009.0010.
[23]
Lawal, T.O.; Adeniyi, B.A.; Moody, J.O.; Mahady, G.B. Combination studies of Eucalyptus torelliana (F MUELL) leaf extract and clarithromycin on H. pylori. Helicobacter 2010, 15, 336. Abstract.
[24]
Gant, V.A.; Wren, M.W.; Rollins, M.S.; Jeanes, A.; Hickok, S.S.; Hall, T.J. Three novel highly charged copper based biocides: Safety and efficacy against healthcare associated organisms. J. Antimicrob. Chemother. 2007, 60, 294–299, doi:10.1093/jac/dkm201.
[25]
Shaikh, A.R.; Yadav, M.; Giridhar, R. Antibiotic metal complexes—An approach for Helicobacter therapy. Helicobacter 2010, 15, 341. Abstract.
[26]
Cervantes, C.; Gutierrez-Corona, F. Copper resistance mechanisms in bacteria and fungi. FEMS Microbiol. Rev. 1994, 14, 121–138, doi:10.1111/j.1574-6976.1994.tb00083.x.
[27]
Sagripanti, J.L.; Routson, L.B.; Lytle, C.D. Virus inactivation by copper or iron ions alone and in the presence of peroxide. Appl. Environ. Microbiol. 1993, 59, 4374–4376.
[28]
Kim, J.H.; Cho, H.; Ryu, S.E.; Choi, M.U. Effects of metal ions on the activity of protein tyrosine phosphatise VHR: Highly potent and reversible oxidative inactivation by Cu2+ ion. Arch. Biochem. Biophys. 2000, 382, 72–80.
[29]
Hall, T.J.; Wren, M.W.; Jeanes, A.; Gant, V.A. A comparisonof the antibacterial efficacy and cytotoxicity to cultured human skin cells of 7 commercial hand rubs and Xgel, a new copper-based biocidal hand rub. Am. J. Infect. Control. 2009, 37, 322–326, doi:10.1016/j.ajic.2008.09.011.
Silen, W.; Ito, S. Mechanisms for rapid re-epithelialization of the gastric mucosal surface. Annu. Rev. Physiol. 1985, 47, 217–229, doi:10.1146/annurev.ph.47.030185.001245.
[32]
Wallace, J.L. Mechanisms of protection and healing: Current knowledge and future research. Am. J. Med. 2001, 110, 19S–23S.
[33]
Konturek, S.J.; Dembinski, A.; Warzecha, Z.; Brzozoski, T.; Gregory, H. Role of epidermal growth factor in healing of chronic gastroduodenal ulcers in rats. Gastroenterology 1992, 94, 1300–1307.
[34]
Borkow, G.; Gabbay, J.; Dardik, R.; Eidelman, A.I.; Lavie, Y.; Grunfeld, Y.; Ikher, S.; Huszar, M.; Zatcoff, R.C.; Marikovsky, M. Molecular mechanisms of enhanced wound healing by copper-oxide impregnated dressings. Wound Repair Regen. 2010, 18, 266–275, doi:10.1111/j.1524-475X.2010.00573.x.
[35]
D’Andrea, L.D.; Romanelli, A.; Di Stasi, R.; Pedone, C. Bioinorganic aspects of angiogenesis. Dalton Trans. 2010, 39, 7625–7636, doi:10.1039/c002439b.
[36]
Megraud, F.; Lehors, P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin. Microbiol. Rev. 2007, 20, 280–322, doi:10.1128/CMR.00033-06.
